fig5

Leelamine suppresses cMyc expression in prostate cancer cells <i>in vitro </i>and inhibits prostate carcinogenesis <i>in vivo</i>

Figure 5. The effect of leelamine (LLM) treatment on cancer incidence in Hi-Myc mice. The effect of LLM treatment on the protein level of cMyc in Myc-CaP cell line as determined by western blotting. The blot was probed with an anti-GAPDH antibody to correct for differences in protein loading. The numbers above bands represent quantitation of the cMyc protein level change relative to corresponding ethanol-treated control. Similar results were obtained in repeated experiments (A). Confocal microscopic images of cMyc protein (green fluorescence) in vehicle-treated control and LLM-treated Myc-CaP cells. DRAQ5 (blue fluorescence) was used for nuclear staining. Similar results were obtained in repeated experiments (B). Body weights of control and LLM-treated Hi-Myc mice (n = 10). Statistical significance was determined by Student’s t-test. LLM treatment did not cause a significant weight loss in Hi-Myc mice (C). Representative H&E-stained sections of the prostate from control and LLM-treated Hi-Myc mice (40x objective magnification, scale bar = 50 µm) (D). The effect of LLM administration on incidence of different histopathologic stages of prostate cancer in Hi-Myc mice (n = 10). Statistical significance was determined by Fisher’s test (E).

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/